EODData

MEMBERSHIP REGISTER LOG IN

FRA, 6Z4: Crinetics Pharmaceuticals Inc

27 Mar 2026
LAST:

31.00

CHANGE:
 1.40		OPEN:
31.00		HIGH:
31.00		ASK:
0.00		VOLUME:
0
CHG(%):
4.79		PREV:
29.20		LOW:
31.00		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Mar 2631.0031.0031.0031.000
26 Mar 2630.6030.6030.6030.60251
25 Mar 2629.2029.2029.2029.20251
24 Mar 2629.2029.2029.2029.20251
23 Mar 2629.8029.8029.8029.80251
20 Mar 2630.2030.2030.2030.20251
19 Mar 2630.6030.6030.6030.600
18 Mar 2632.4032.4032.4032.400
17 Mar 2631.6031.6031.6031.600
16 Mar 2632.4032.4032.4032.400

PROFILE

Name:Crinetics Pharmaceuticals Inc
About:Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:6055 Lusk Boulevard, San Diego, CA, United States, 92121
Website:https://www.crinetics.com
ISIN:US22663K1079
LEI:549300Q1CNFXK5P31D28

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-8.08 
Forward P/E:-9.93 
PEG Ratio:-9.93 
Price to Sales:2,214.85 
Price to Book:3.10 
Operating Margin:-997.10 
Return on Assets:-0.28 
Return on Equity:-0.44 
Revenue:1.3M 
Shares:94.18M 
Market Cap:2.919B 

TECHNICAL INDICATORS

MA5:29.804.0%
MA10:30.701.0%
MA20:31.842.7%
MA50:34.059.8%
MA100:30.272.4%
MA200:29.375.5%
STO9:43.75
STO14:38.89
RSI14:38.30 
WPR14:-61.11
MTM14:-2.20
ROC14:-0.07 
ATR:0.73 
Week High:30.601.3%
Week Low:29.206.2%
Month High:36.0016.1%
Month Low:29.205.5%
Year High:43.4040.0%
Year Low:22.3538.7%
Volatility:32.01